Chronic treatment with human recombinant ...



Title Chronic treatment with human recombinant erythropoietin increases hematocrit and improves water maze performance in mice
Author(s) J. M. Hengemihle, O. Abugo, J. Rifkind, Elizabeth Spangler, D. Danon, D. K. Ingram
Journal Physiology & Behavior
Date 1996
Volume 59
Issue 1
Start page 153
End page 156
Abstract Erythropoietin is a glycoprotein produced endogenously in the kidney, which stimulates red blood cell production. We evaluated the effects of chronic treatment with recombinant human erythropoietin (epoetin alfa: EPO) on the performance of 6-month-old male C57BL/6J mice in a spatial learning task, the Morris water maze. Mice were treated with either EPO (1.5 U injected SC every other day) or vehicle (PBS also injected SC every other day). Results indicated that the treatment had no effect on maze performance after 8 weeks, but after 19 weeks the EPO-treated mice showed better performance compared to controls as measured by mean distance (centimeters) to reach the goal platform. The improved performance in EPO-treated mice at 19 weeks was accompanied by an increased hematocrit. After 32 wk of EPO-treatment, the hematocrit returned to baseline levels even though the size and density of the red blood cells were increased.

Using APA 6th Edition citation style.

[Page generation failure. The bibliography processor requires a browser with Javascript enabled.]

Times viewed: 439

Adding this citation to "My List" will allow you to export this citation in other styles.